Royalties to PDL. Subject to reduction for any offset as provided in Section 3.05, or withholding under Section 3.09(b), and in further consideration of the rights and licenses granted under Article 2, TANOX shall pay to PDL a royalty of * of the Net Sales of all Licensed Products sold by TANOX or its Affiliates or sublicensees in each country until the last date on which there is a Valid Claim that, but for a license granted to TANOX under this Agreement, would be infringed by the making, using, having made or sale of that Licensed Product in such country or by the manufacture of Licensed Product in the country of manufacture.
Royalties to PDL. The royalties payable to PDL under this PDL License Agreement shall be as set forth in Section 4.1 of the Master Agreement, except that in the event that GNE: (i) breaches its obligations under Sections 2.3 or 2.4 of the Settlement Agreement by and between PDL and GNE dated December 18, 2003 (“Settlement Agreement”); and (ii) fails to cure such breaches as provided under Section 4.2 of the Settlement Agreement, then PDL, at its sole discretion, may invoke its rights under Article 4 of the Settlement Agreement.
Royalties to PDL. Subject to reduction for any offset as provided in Section 3.05, in further consideration of the rights and licenses granted under Article 2, ELAN shall pay to PDL a royalty of [ ] of the Net Sales of all Licensed Products sold by ELAN or its Affiliates or sublicensees in each country until the last date on which there is a Valid Claim that, but for the licenses granted to ELAN under this Agreement, would be infringed by the making, using, having made or sale of that Licensed Product in such country or by the manufacture of Licensed Product in the country of manufacture.
Royalties to PDL. In further consideration of the licenses granted under this Agreement, HGS shall pay to PDL on a country-by-country basis a royalty of [****]* of the Net Sales of all Licensed Products sold by HGS or its Affiliates or sublicensees or by a successor in interest to the CoGenesys division of HGS in each country until the last date on which there is a Valid Claim that, but for the licenses granted to HGS under this Agreement, would be infringed by the importation, making, using, having made or sale of that Licensed Product in such country or by the manufacture of Licensed Products in the country of manufacture. After the Effective Date, HGS shall not pay any additional or related royalties for any additional Licensed PDL Patents covering Licensed Products that may issue in the future in any country.
Royalties to PDL. In further consideration of the licenses granted under this Agreement, Seattle Genetics shall pay to PDL on a country-by-country basis a royalty of [*] of the Net Sales of all Licensed Products sold by Seattle Genetics or its Affiliates or sublicensees in each country until the last date on which there is a Valid Claim that, but for the licenses granted to Seattle Genetics under this Agreement, would be infringed by the importation, making, using, having made or sale of that Licensed Product in such country or by the manufacture of Licensed Products in the country of manufacture. After the Effective Date, Seattle Genetics shall not pay any additional or related royalties for any additional Licensed PDL Patents covering Licensed Products that may issue in the future in any country.
Royalties to PDL. In further consideration of the rights and licenses granted under Article 2 of this Agreement, subject to Section 2.05, SB shall pay to PDL the following royalties on Net Sales of Licensed Product sold by SB, its Affiliates or sublicensees, as applicable: [CONFIDENTIAL TREATMENT REQUESTED] 3.04
Royalties to PDL. In further consideration of the rights and licenses granted hereunder, SANDOZ shall pay to PDL a royalty of [ ] of the Net Sales Value of all Licensed Products sold by SANDOZ or its Affiliates or sublicensees for a period of [ ] years from the date of first sale of any Licensed Product in each country. In the event that SANDOZ desires to sublicense its rights hereunder and finds that, despite its good faith best efforts, it is unable to do so solely because of this royalty rate, the parties shall negotiate in good faith to reduce such rate to a rate which is economically beneficial to both parties and permits such sublicensing.
Royalties to PDL. (a) Royalties. Subject to Section 5.03(c) and, if applicable, Section 6.01, in further consideration of the rights and licenses granted by PDL under Section 3.01, PROGENICS shall pay to PDL a royalty of Four and One-Half Percent (4.5%) on the Net Sales of all Licensed Products sold by PROGENICS or its Affiliates or sublicensees.
Royalties to PDL. In further consideration of the rights and licenses granted under Article 2, GNE shall pay to PDL a royalty of [ ] of the Net Sales of all GNE Licensed Products sold by GNE or its Affiliates or sublicensees or Roche in each country in the Territory until the later of the last date on which there is a Valid Claim that, but for the licenses granted to GNE under this Agreement, would be infringed by the making, using, importation, having made or sale of that Licensed Product in such country in the Territory or by the manufacture of Licensed Product in the country of manufacture. [Drafting Note: Include the following sentence if the licensed Antibody is a bispecific antibody: "If the Antigen is the target of one arm of a bispecific antibody, then both arms shall be considered one Licensed Product for purposes of calculating royalties with respect to such Licensed Product, and GNE shall pay a royalty of [ ] of Net Sales GNE, its Affiliates or sublicensees or Roche."]
